ClearPoint Neuro, Inc. (CLPT), previously known as MRI Interventions, Inc., is a global medical device and biologics company dedicated to improving and saving lives by enabling minimally invasive procedures with real-time, intra-procedural magnetic resonance imaging (MRI). With its corporate headquarters in Solana Beach, California, U.S., the company has additional offices in Irvine, California, and Knoxville, Tennessee.
ClearPoint Neuro specializes in neuro-navigation, much like how GPS guides drivers to their destination. Its groundbreaking technology, the ClearPoint Neuro Navigation System, is the only platform in the world that provides real-time visualization during neurosurgeries. Physicians can see inside the patient's brain in real-time during procedures for more precise, safer, and less invasive surgeries.
This innovative system has broad applications across various therapeutic areas, including deep brain stimulation (DBS), laser interstitial thermal therapy (LITT), biopsy, catheter and electrode placement, and more. It has revolutionized the field of neurosurgery, making surgical procedures safer and more effective, offering patients faster recovery times and better outcomes.
Furthermore, ClearPoint Neuro is at the forefront of drug delivery for neurological disorders, enhancing direct drug delivery to specific areas of the brain with its technology and proprietary biologics. This capability breaks barriers to brain treatments and allows for new possibilities in neuro-oncology and neuro-degenerative diseases, such as Alzheimer's and Parkinson's disease. This is achieved by facilitating drug companies to localize and optimize the delivery of their drugs or cells directly to critical areas of the brain.
CLPT is committed to improving the quality of life for patients living with various neurological disorders by allowing more accurate surgical procedures, minimizing trauma, reducing costs, and improving recovery times. Their innovative technology and biologics solutions have the potential to significantly advance treatment for those suffering from some of the most devastating neurological diseases, offering hope for a better quality of life. ClearPoint Neuro upholds the highest standards of safety, efficiency, and accuracy in its operations, earning the trust of physicians, patients, and families alike.
Being publicly traded on the Nasdaq under the ticker symbol "CLPT," ClearPoint Neuro continues to make strides in the medical world and introduces significant advancements at the cross-section of technology, biologics, and neuroscience. The company's efforts are pushing the boundaries of what's possible in neurosurgery and drug delivery, a testament to its dedication to improving and saving lives. Overall, ClearPoint Neuro sits at the forefront of the neurosurgical industry, pioneering innovative solutions and shaping the future of neuroscience treatment.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article analyzes Clearpoint Neuro, Inc. (NASDAQ: CLPT) using AI models, highlighting weak near-term sentiment that may lead to a resumption of long-term weakness after a neutral shift. It identifies an exceptional 132.5:1 risk-reward setup, targeting a 41.9% gain versus 0.3% risk. The analysis provides specific institutional trading strategies, including position, momentum, and risk hedging, along with multi-timeframe signal analysis.
ClearPoint Neuro (CLPT) reported Q1 2026 revenue of $12.13 million, a 43% year-over-year increase, but missed the Zacks Consensus Estimate by 1%. The company posted an EPS of -$0.32, which was below the consensus estimate of -$0.28. Despite the earnings miss, key metrics like Neurosurgery navigation and therapy revenue and Capital equipment and software revenue saw significant year-over-year growth.
ClearPoint Neuro, Inc. (CLPT) reported a Q1 loss of $0.32 per share, missing the Zacks Consensus Estimate of a $0.28 loss, and also fell short of revenue expectations with $12.13 million against an $8.48 million year-ago figure. The company has consistently missed EPS estimates over the last four quarters and has only topped revenue estimates once in that period. Given the unfavorable estimate revision trend, Zacks has issued a Rank #4 (Sell) for CLPT, suggesting potential underperformance in the near future.
Conway Capital Management Inc. has initiated a new position in ClearPoint Neuro, Inc. (NASDAQ:CLPT) by purchasing 92,975 shares valued at approximately $1.66 million, making it their 21st largest holding. This investment contributes to the increasing institutional ownership in ClearPoint Neuro, which now stands at 30.08%, with other major firms like BlackRock also acquiring stakes. Despite recent weaker-than-expected quarterly results and mixed analyst ratings, the company continues to see significant institutional interest.
This article from Stock Traders Daily analyzes Clearpoint Neuro, Inc. (NASDAQ: CLPT) focusing on its price dynamics and execution-aware positioning. It identifies a strong near-term sentiment despite broader weak alignment, highlighting an exceptional 142.5:1 risk-reward setup targeting a 44.2% gain. The analysis provides specific institutional trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Wall Street Zen has downgraded ClearPoint Neuro (NASDAQ:CLPT) to a "strong sell" rating, despite other analysts having a mixed view with a consensus "Hold" rating and a target price of $25.67. The downgrade follows ClearPoint Neuro missing its quarterly earnings expectations, reporting an adjusted loss of $0.38 per share against an estimated $0.29 loss, and revenue of $10.88 million versus $12.73 million expected. Additionally, company insiders have sold over 108,000 shares worth approximately $1.8 million in the past three months, while institutional investors hold 30.08% of the company.
ClearPoint Neuro, Inc. (NASDAQ:CLPT) recently missed its second-quarter earnings expectations, with revenues 15% below forecasts and statutory losses increasing significantly. As a result, analysts have downgraded revenue estimates and increased loss per share forecasts for 2026, leading to a 9.4% reduction in the consensus price target to US$25.67. Despite the negative revisions, the company is still projected to experience faster revenue growth than the wider industry.
ClearPoint Neuro, Inc. (NASDAQ:CLPT) recently missed its second-quarter earnings expectations, with revenues 15% below forecasts and statutory losses increasing significantly. This has led analysts to downgrade revenue estimates for 2026 and project higher per-share losses, resulting in a 9.4% reduction in the consensus price target. Despite the lowered outlook, analysts still expect ClearPoint Neuro to grow faster than the broader industry.